参考文献/References:
[1]AUDIA S,MAHEVAS M,NIVET M,et al.Immune thrombocytopenia:Recent advances in pathogenesis and treatments[J].Hemasphere,2021,5(6):e574.
[2]PALANDRI F,ROSSI E,BARTOLETTI D,et al.Realworld use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia[J].Blood,2021,138(7):571-583.
[3]PROVAN D,SEMPLE J W.Recent advances in the mechanisms and treatment of immune thrombocytopenia[J].Bio Medicine,2022,76:103820.
[4]蓝海,侯丽,郎海燕,等.常见血液病的中医分类与命名[J].中医杂志,2019,60(9):750-753,778.
[5]许振国.“三”、“负阴抱阳”、“冲气”解诂[J].河南中医,1999,19(3):69-70.
[6]田明杰.吴澄《道德真经注》老学思想研究[D].保定:河北大学,2023.
[7]黄芸丹.焦循《论语通释》研究[D].杭州:浙江工商大学,2023.
[8]LIU L,HUA M,LIU C,et al.The aberrant expression of microRNAs and correlations with T cell subsets in patients with immune thrombocytopenia[J].Oncotarget,2016,7(47):76453-76463.
[9]LI W,WANG X,LI J,et al.A study of immunocyte subsets and serum cytokine profiles before and after immunal suppression treatment in patients with immune thrombocytopenia[J].Zhonghua Nei Ke Za Zhi,2016,55(2):111-115.
[10]LIN X,XU A,ZHOU L,et al.Imbalance of T lymphocyte subsets in adult immune thrombocytopenia[J].Int J Gen Med,2021,14:937-947.
[11]魏佩佩,方代华.儿童ITP 外周血Th1、Th2、Th17、Treg细胞表达及临床意义[J].临床输血与检验,2020,22(2):168-171.
[12]CHEN Y Y,ZHOU Y Q,ZHAO N,et al.Evaluation of IVIG response in relation to Th1/Th2 cytokines in pediatricm immune thrombocytopenia[J].Cytokine,2019,120(31):234-241.
[13]CRANE I J,FORRESTER J V.Th1 and Th2 lymphocytes in autoimmune disease[J].Crit Rev Immunol,2005,25(2):75-102.
[14]VRBENSKY J R,NAZY I,CLARE R,et al.T cell-mediated autoimmunity in immune thrombocytopenia[J].Eur J Haematol,2022,108(1):18-27.
[15]GOSCHL L,SCHEINECKER C,BONELLI M.Treg cells in autoimmunity:From identification to Treg-based therapies[J].Semin Immunopathol,2019,41(3):301-314.
[16]ZHANG J B,MA D X,ZHU X J,et al.Elevated profile of Th17,Th1 and Tc1 cells in patients with immune thrombocytopenic purpura[J].Haematologica,2009,94(9):1326-1329.
[17]左楠,王远,王爽.骨髓间充质干细胞移植联合多点微量注射曲安奈德对兔耳增生性瘢痕及创面巨噬细胞极化的影响[J].陕西医学杂志,2022,51(2):140-144.
[18]冯琦.巨噬细胞极化和HLA-G 异常在ITP中的作用和调控研究[D].济南:山东大学,2017.
[19]ZHANG X,WANG Y,ZHANG D,et al.CD70-silenced dendritic cells induce immune tolerance in immune thrombocytopenia patients[J].Br J Haematol,2020,191(3):466-475.
[20]杨冉,林琳,沈群.原发免疫性血小板减少性免疫性血小板减少性紫癜相关性疲劳的研究进展[J].中国实用内科杂志,2020,40(3):252-255.
[21]魏丢,唐旭东,许勇钢,等.麻柔教授基于扶阳思想辨治免疫性血小板减少性紫癜经验总结[J].陕西中医,2021,42(9):1279-1281.
[22]李捷凯,鲍计章,朱文伟,等.周永明基于“阴火”学说治疗原发免疫性血小板减少症经验[J].陕西中医,2020,41(12):1793-1795.
[23]张瑞雪.以“阳虚而郁”立论谈“易阳通元”法则[J].陕西中医药大学学报,2020,43(4):78-81.
[24]张园园,丁惠玲,魏淑相,等.情志学说的历史与临床应用[J].中医临床研究,2022,14(26):28-31.
[25]宁萍,原宁.艾曲泊帕治疗慢性免疫性血小板减少症疗效及对患儿免疫学指标的影响[J].陕西医学杂志,2021,50(10):1279-1281,1288.
相似文献/References:
[1]孟庆怡,唐苾芯,吴昆仑△.中医治疗血液病药对应用探讨*[J].陕西中医,2019,(9):1265.
[2]郝亚娟,薛敬东△.试析从肝辨证论治血液病及薛敬东教授临证经验*[J].陕西中医,2020,(3):377.
[3]李晓靖,鲍计章,朱文伟,等.周永明辨治原发免疫性血小板减少症经验[J].陕西中医,2021,(8):1115.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.032]
LI Xiaojing,BAO Jizhang,ZHU Wenwei,et al.ZHOU Yongming's experience in treating primary immune thrombocytopenia based on syndrome differentiation[J].,2021,(6):1115.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.032]
[4]竺 佳,杨向东,房丽君,等.中医辨治原发免疫性血小板减少症研究进展[J].陕西中医,2023,(11):1660.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.041]